Get the Stockscreener App
48.85
2.37%
1.13
After Hours:
48.85
Akero Therapeutics Inc stock is traded at $48.85, with a volume of 1.02M.
It is up +2.37% in the last 24 hours and down -8.45% over the past month.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.
See More
Previous Close:
$47.72
Open:
$47.64
24h Volume:
1.02M
Relative Volume:
0.67
Market Cap:
$3.89B
Revenue:
-
Net Income/Loss:
$-269.44M
P/E Ratio:
-13.03
EPS:
-3.75
Net Cash Flow:
$-262.63M
1W Performance:
-3.29%
1M Performance:
-8.45%
6M Performance:
-9.67%
1Y Performance:
+82.75%
1-Day Range:
$47.50
$49.36
1-Week Range:
$46.92
$50.83
52-Week Range:
$21.34
$58.40
Akero Therapeutics Inc Stock (AKRO) Company Profile
Name
Akero Therapeutics Inc
Sector
Industry
Phone
650-487-6488
Address
601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO, CA
Compare AKRO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AKRO
Akero Therapeutics Inc
|
48.85 | 3.80B | 0 | -269.44M | -262.63M | -3.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Akero Therapeutics Inc Stock (AKRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-25 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-27-25 | Reiterated | H.C. Wainwright | Buy |
| Nov-18-24 | Initiated | Citigroup | Buy |
| Apr-22-24 | Resumed | BofA Securities | Neutral |
| Sep-19-23 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-28-23 | Initiated | UBS | Buy |
| Jan-27-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-14-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-19-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-10-21 | Initiated | BofA Securities | Buy |
| Feb-26-21 | Initiated | Guggenheim | Buy |
| Sep-10-20 | Initiated | Morgan Stanley | Overweight |
| Jul-20-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-07-20 | Initiated | Chardan Capital Markets | Buy |
| Jul-01-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-02-20 | Initiated | H.C. Wainwright | Buy |
| Feb-10-20 | Initiated | Canaccord Genuity | Buy |
| Jul-15-19 | Initiated | Evercore ISI | Outperform |
| Jul-15-19 | Initiated | JP Morgan | Overweight |
| Jul-15-19 | Initiated | Jefferies | Buy |
| Jul-15-19 | Initiated | ROTH Capital | Buy |
View All
Akero Therapeutics Inc Stock (AKRO) Latest News
What are the latest earnings results for Akero Therapeutics Inc.Daily Trading Opportunities For Fast Growth - jammulinksnews.com
Published on: 2025-07-31 11:02:34 - metal.it
Akero Therapeutics Inc. Forms Bullish Flag — Upside AheadLow Capital High Return Stock Plans Reviewed - beatles.ru
Will Akero Therapeutics Inc. Benefit From Broader Market BounceWeekly Stock Watch With Growth Focus Expanded - metal.it
33,611 Shares in Akero Therapeutics, Inc. (NASDAQ:AKRO) Bought by Picton Mahoney Asset Management - MarketBeat
Victory Capital Management Inc. Increases Stock Position in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Skandinaviska Enskilda Banken AB publ Invests $311,000 in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Akero Therapeutics Inc. Ranks High in Smart Money TrackerDaily Smart Money Movement Monitor Activated - beatles.ru
How Akero Therapeutics Inc. stock performs during market volatilityWeekly Watchlist of High Movers Released - beatles.ru
Teachers Retirement System of The State of Kentucky Trims Stock Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
What makes Akero Therapeutics Inc. stock price move sharplyMarket Forecast Picks That Work - jammulinksnews.com
How strong is Akero Therapeutics Inc. company’s balance sheetFree Daily Trading Room Entry - jammulinksnews.com
What are the technical indicators suggesting about Akero Therapeutics Inc.Build a diversified portfolio for maximum returns - jammulinksnews.com
Is it the right time to buy Akero Therapeutics Inc. stockSuperior capital gains - jammulinksnews.com
Is Akero Therapeutics Inc. a growth stock or a value stockUnlock expert trading strategies for growth - jammulinksnews.com
Jennison Associates LLC Invests $533,000 in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
100,500 Shares in Akero Therapeutics, Inc. (NASDAQ:AKRO) Acquired by Readystate Asset Management LP - MarketBeat
Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock Holdings Lowered by Kennondale Capital Management LLC - MarketBeat
AstraZeneca’s Anselamimab Misses Primary Endpoint in Amyloidosis Trials, Shows Promise in Subgroup - MSN
What analysts say about Akero Therapeutics Inc. stockTremendous growth potential - PrintWeekIndia
Is Akero Therapeutics Inc. a good long term investmentFast-track wealth growth - PrintWeekIndia
What drives Akero Therapeutics Inc. stock priceHigh-margin investment plays - PrintWeekIndia
Bank of New York Mellon Corp Purchases 12,235 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Is Akero Therapeutics Inc. stock a growth or value playFree Trend-Following Techniques - jammulinksnews.com
How to Take Advantage of moves in (AKRO) - news.stocktradersdaily.com
Edgestream Partners L.P. Acquires Shares of 6,947 Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Akero Therapeutics Inc. Stock Analysis and ForecastFastest-growing stock picks - Autocar Professional
5,565 Shares in Akero Therapeutics, Inc. (NASDAQ:AKRO) Bought by Xponance Inc. - MarketBeat
Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells $529,500.00 in Stock - MarketBeat
Akero Therapeutics Inc Stock (AKRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):